2024. A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of long-Acting Injectable Formulation of Vanoxerine (Vanoxerine Consta 394.2 mg) for Treatment of Amphetamine-Type Stimulant (ATS) Dependence. London Journal of Medical and Health Research. 24, 6 (Jul. 2024), 63–87.